Highlights

  • Ryman Healthcare recorded 379 retirement living sales agreements in Q2 FY27, including 312 resales.
  • Resales increased 14% year-on-year, reaching their highest quarterly level in eight quarters.
  • Cogstate reported stronger clinical trial contracting activity, supported by demand across central nervous system research.
  • Aroa Biosurgery released positive clinical trial results for its Symphony diabetic foot ulcer treatment.

Ryman Healthcare (ASX:RYM), a retirement living and aged care operator with operations in New Zealand and Australia, reported stronger resale activity in its second-quarter FY27 trading update released on 12 October 2026.

The company operates integrated retirement communities offering independent living, assisted living and aged care services.

Despite subdued housing market conditions, Ryman reported continued demand for retirement accommodation and care services across its operating markets.

For the three months ended 30 September 2026, Ryman Healthcare (ASX:RYM) recorded 379 retirement living occupation right agreements, comprising 312 resales and 67 new sales.

Resale volumes increased 14% compared with the corresponding quarter of the previous year, representing the strongest quarterly resale performance in eight quarters.

Net resale contract volumes also increased 11% year-on-year, following 7% growth in Q1 FY27.

The improvement indicates continued activity in the company's existing retirement village portfolio, even as housing market conditions remain challenging.

Retirement Village Inventory and Aged Care Occupancy Improve

Ryman Healthcare (ASX:RYM) also reported progress in reducing unsold retirement living inventory.

During Q2 FY27, its new retirement living stock declined by 67 units to 347, bringing the reduction since 31 March 2026 to 132 units.

The decrease reflected new sales and the planned absence of new stock deliveries during the first half of FY27.

Meanwhile, total aged care occupancy reached 94.0%, representing an improvement of 3.3 percentage points compared with the corresponding period of FY26.

Occupancy at mature aged care centres stood at 95.4%, compared with 95.7% a year earlier. The company attributed the slight decline to winter-related illness affecting certain New Zealand villages.

In Victoria, occupancy across five mature aged care centres increased to 97.9% from 96.1% in the prior corresponding quarter.

These figures demonstrate improving utilisation across recently developed care facilities while highlighting some variation across established locations.

Ryman Healthcare Progresses FY27 Development Plans

Ryman Healthcare (ASX:RYM) continued expanding its retirement living and aged care capacity through the Richard Hadlee Village development in Christchurch.

The new main building opened in October 2026, adding 77 retirement living units and 65 care beds.

Following the completion of these facilities, Ryman maintained its FY27 development guidance of 157–168 retirement living units and aged care beds.

The company is also implementing initiatives designed to improve affordability and accessibility for prospective residents.

These include targeted sales strategies, additional pricing options and greater flexibility in retirement living services.

Ryman Healthcare (ASX:RYM) aims to match resale volumes with resident turnover by the end of FY27, supporting its broader focus on operating efficiency and cash flow.

Cogstate Reports Increased Clinical Trial Contracting Activity

Cogstate (ASX:CGS), a healthcare technology company specialising in cognitive assessments and clinical trial measurement, reported further contracting activity during the September 2026 quarter.

The company secured US$25.1 million in net sales contracts, compared with approximately US$21.4 million in the corresponding period of FY26.

Its activities included five Phase III clinical studies involving bipolar disorder and depression across two customers.

These agreements reflect continued demand for cognitive assessment services in central nervous system research.

Cogstate (ASX:CGS) also reported that contracted revenue expected to be recognised during FY27 increased to US$56.8 million, compared with US$48.3 million at 30 June 2026.

Contracted revenue represents services expected to be delivered over the relevant contract periods rather than revenue already recognised.

Future revenue recognition will depend on clinical trial schedules, contractual milestones and the timing of service delivery.

Aroa Biosurgery Reports Positive Symphony Clinical Trial Results

Aroa Biosurgery (ASX:ARX), a medical technology company developing regenerative tissue products, reported positive clinical evidence supporting its Symphony wound treatment.

The company announced results from a randomised controlled trial involving 143 patients across 10 United States clinical sites.

The study evaluated Symphony alongside standard care for diabetic foot ulcers.

Within 12 weeks, 55% of ulcers treated using Symphony and standard care achieved complete closure, compared with 35% receiving standard care alone.

The average healing time was 65.4 days in the Symphony group, compared with 73.2 days for patients receiving standard care alone.

The results demonstrated statistically significant improvements in wound closure and healing time within the study population.

Aroa Biosurgery (ASX:ARX) intends to use the clinical evidence to support discussions with healthcare providers and reimbursement stakeholders in the United States.

However, broader commercial adoption will depend on reimbursement arrangements, clinician acceptance and market access requirements.

Other Healthcare Companies Face Different Operating Conditions

Other Australian healthcare companies continue navigating developments specific to their businesses.

CSL (ASX:CSL) remains focused on plasma collection, biotechnology manufacturing and the development of its global healthcare operations.

Regis Healthcare (ASX:REG) continues operating residential aged care services in Australia, where occupancy, workforce availability and regulatory requirements remain important operational considerations.

The different business models across retirement living, clinical research technology, biotechnology and aged care demonstrate the varied factors influencing Australia's listed healthcare sector.

Key Insights

Ryman Healthcare's (ASX:RYM) Q2 FY27 update demonstrated improving retirement living resales and aged care occupancy despite soft housing conditions.

The company's future financial performance will depend partly on converting contracted sales into settlements, managing development expenditure and maintaining operating efficiency.

Meanwhile, Cogstate (ASX:CGS) reported increased contracted revenue visibility, while Aroa Biosurgery (ASX:ARX) strengthened the clinical evidence supporting its Symphony product.

As of 12 October 2026, these developments highlight differing sources of operational progress across retirement living, clinical research and medical technology.